Jordi Rodon

Summary

Affiliation: Cancer Therapy and Research Center
Country: USA

Publications

  1. ncbi Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite 414, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 62:911-9. 2008
  2. ncbi Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1
    Anthony W Tolcher
    South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA
    J Clin Oncol 27:5800-7. 2009
  3. ncbi A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 69:825-34. 2012
  4. ncbi Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Chia Chi Lin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 63:1065-71. 2009

Collaborators

Detail Information

Publications4

  1. ncbi Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite 414, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 62:911-9. 2008
    ..This provided the rationale for the three-times weekly treatment explored in this protocol...
  2. ncbi Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1
    Anthony W Tolcher
    South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA
    J Clin Oncol 27:5800-7. 2009
    ..To determine the maximum-tolerated dose (MTD) and to assess the safety, pharmacokinetics, and evidence of antitumor activity of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 (IGF-1R)...
  3. ncbi A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 69:825-34. 2012
    ..The primary objective of this study was to determine whether repeated doses of bexarotene capsules affect pharmacokinetic parameters of paclitaxel or carboplatin in patients with advanced non-small cell lung cancer...
  4. ncbi Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Chia Chi Lin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 63:1065-71. 2009
    ....